Resumen de Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence

Douglas Guedes de Castro, Carlos Henrique Andrade Teixeira, Guilherme Rocha Melo Gondim, Patrícia Bailão Aguilar, Marcos André de Sá Barreto Costa, Thiago William Carnier Jorge, Rodrigo de Morais Hanriot

• Purpose To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting.

  Methods/patients The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan–Meier and log-rank test was applied.

  Results After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034).

  Conclusions This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.